scispace - formally typeset
G

Gary C. Brown

Researcher at Thomas Jefferson University

Publications -  264
Citations -  9480

Gary C. Brown is an academic researcher from Thomas Jefferson University. The author has contributed to research in topics: Macular degeneration & Visual acuity. The author has an hindex of 53, co-authored 262 publications receiving 8909 citations.

Papers
More filters
Journal ArticleDOI

Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration

Wei Chen, +69 more
TL;DR: A genome-wide association scan for age-related macular degeneration (AMD) showed that 329 of 331 individuals with the highest-risk genotypes were cases, and 85% of these had advanced AMD, consistent with the hypothesis that HDL metabolism is associated with AMD pathogenesis.
Journal ArticleDOI

Aspirin Effects on Mortality and Morbidity in Patients With Diabetes Mellitus: Early Treatment Diabetic Retinopathy Study Report 14

Aaron Kassoff, +147 more
- 09 Sep 1992 - 
TL;DR: The early treatment diabetic retinopathy study (ETDRS) as mentioned in this paper was a randomized clinical trial of aspirin vs placebo, which was sponsored by the National Eye Institute (NIEI).
Journal ArticleDOI

Congenital Pits of the Optic Nerve Head: II. Clinical Studies in Humans

TL;DR: The clinical characteristics of 75 eyes with congenital pits of the optic nerve head were reviewed, particularly in relation to associated serous retinal detachment as discussed by the authors, and clinical evidence was presented supporting the theory that the associated subretinal fluid is derived from liquified vitreous.
Journal ArticleDOI

Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy.

TL;DR: The study documents increased levels of basic fibroblast growth factor in vitreous specimens from patients with proliferative diabetic retinopathy, particularly those with active proliferative Retinopathy.
Journal ArticleDOI

Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.

TL;DR: Most patients in whom presumed infectious endophthalmitis develop after anti-VEGF injection regained baseline vision after treatment, and a low threshold for vitreous tap with intravitreal antibiotic injection may be warranted.